Skip to main content
Universal Drugstore logo

Who Qualifies for Jardiance?

Jardiance (empagliflozin) has become one of the most versatile medications in modern medicine, with multiple FDA-approved uses beyond its original purpose. Understanding who qualifies for this SGLT2 inhibitor can help patients and healthcare providers determine if it’s the right treatment option.

Shop Medications

,

In This Article

FDA-Approved Uses of Jardiance

The FDA has approved Jardiance for four distinct medical conditions. Each indication has specific patient criteria that determine eligibility.

Type 2 Diabetes Management

Jardiance is approved as an adjunct to diet and exercise to improve blood sugar control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus.1 This means the medication works alongside lifestyle changes, not as a replacement for proper diet and exercise habits.

For this indication, patients must have a confirmed diagnosis of type 2 diabetes. The medication is not approved for type 1 diabetes or diabetic ketoacidosis treatment.2

Heart Failure Treatment

Adults with heart failure may qualify for Jardiance to reduce the risk of cardiovascular death and hospitalization for heart failure.3 This indication applies regardless of ejection fraction, meaning it benefits patients with both reduced and preserved heart function.

Patients do not need to have diabetes to qualify for this heart failure indication. The approval came after clinical trials showed significant benefits in heart failure patients with and without diabetes.

Cardiovascular Risk Reduction in Diabetes

For adults with type 2 diabetes and established cardiovascular disease, Jardiance can reduce the risk of cardiovascular death.1 Established cardiovascular disease typically includes a history of heart attack, stroke, or symptomatic coronary artery disease.

The landmark EMPA-REG OUTCOME trial demonstrated a 38% reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease.2

Chronic Kidney Disease Protection

Adults with chronic kidney disease at risk of progression may qualify for Jardiance to reduce the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and hospitalization.1

The EMPA-KIDNEY trial showed that Jardiance 10 mg significantly reduced the risk of kidney disease progression or cardiovascular death by 28% in adults with chronic kidney disease.4

Age Requirements for Jardiance

Age eligibility varies depending on the intended use:

  • Type 2 diabetes management: Adults and pediatric patients 10 years and older
  • Heart failure treatment: Adults only
  • Cardiovascular risk reduction: Adults only
  • Chronic kidney disease: Adults only

For pediatric patients with type 2 diabetes, healthcare providers must carefully weigh the benefits and risks, as this represents off-label use below age 18 for most indications.

Kidney Function Requirements

Kidney function plays a crucial role in determining Jardiance eligibility. The medication works through the kidneys, so proper kidney function is essential for both safety and effectiveness.

Patients with severe kidney impairment or those on dialysis may not be suitable candidates. Healthcare providers typically evaluate kidney function using estimated glomerular filtration rate (eGFR) measurements and may adjust dosing or choose alternative treatments based on these results.

Who Should Not Take Jardiance

Several conditions and circumstances make Jardiance unsuitable or require extreme caution:

Absolute Contraindications

  • Type 1 diabetes: Jardiance is not approved for type 1 diabetes treatment
  • Diabetic ketoacidosis: The medication cannot treat this serious complication
  • Known hypersensitivity: Patients with allergic reactions to empagliflozin or any ingredient should avoid the medication

Conditions Requiring Caution

Certain medical conditions require careful evaluation before starting Jardiance:5

  • Volume depletion: Patients who are dehydrated or have low blood pressure may experience worsening symptoms
  • Recurrent genitourinary infections: History of frequent urinary tract infections or genital infections may indicate higher risk
  • Severe kidney disease: Advanced kidney disease or dialysis patients require alternative treatments
  • History of ketoacidosis: Previous episodes may indicate increased risk

Medical Evaluation Process

Healthcare providers typically follow a systematic approach to determine Jardiance eligibility:

Initial Assessment

The evaluation begins with confirming the diagnosis and reviewing medical history. Providers assess current medications, allergies, and previous treatment responses. A complete physical examination helps identify potential contraindications.

Laboratory Testing

Blood tests typically include kidney function markers, blood sugar levels, and electrolyte balance. Urine tests may check for protein levels and signs of kidney damage. These results help determine appropriate dosing and monitoring requirements.

Risk-Benefit Analysis

Providers weigh the potential benefits against individual risk factors. This analysis considers the patient’s overall health, other medical conditions, and treatment goals. The decision involves both clinical evidence and patient preferences.

Special Populations

Elderly Patients

Older adults may qualify for Jardiance, but require closer monitoring. Age-related changes in kidney function and increased risk of dehydration need consideration. Dosage adjustments may be necessary based on individual health status.

Pregnancy and Breastfeeding

Jardiance is generally not recommended during pregnancy or breastfeeding. Women of childbearing age should discuss family planning with their healthcare provider. Alternative treatments may be more appropriate during these periods.

Patients with Multiple Conditions

Many patients have several medical conditions that could benefit from Jardiance. For example, someone with both diabetes and heart failure may qualify under multiple indications. Healthcare providers coordinate treatment to address all relevant conditions safely.

Insurance and Access Considerations

Insurance coverage for Jardiance often depends on the specific indication and patient circumstances. Most insurance plans cover FDA-approved uses when medical necessity is documented. Prior authorization may be required, especially for newer indications like chronic kidney disease.

For patients concerned about medication costs, exploring cash-pay options through Universal Drugstore may provide more affordable access to Jardiance while maintaining safety and quality standards.

Working with Your Healthcare Provider

Determining Jardiance eligibility requires professional medical evaluation. Patients should discuss their complete medical history, including all medications and supplements. Regular monitoring helps ensure continued safety and effectiveness.

Healthcare providers may start with lower doses and gradually increase based on individual response. Follow-up appointments allow for dosage adjustments and monitoring for side effects. Open communication about symptoms and concerns helps optimize treatment outcomes.

Future Considerations

As research continues, Jardiance eligibility criteria may expand. Ongoing clinical trials investigate additional uses and patient populations. Healthcare providers stay current with evolving guidelines to ensure patients receive appropriate treatment recommendations.

The medication’s versatility across multiple conditions makes it an important option for many patients. However, individual eligibility always depends on specific medical circumstances and professional medical judgment.

References